Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Nov 16:5:2670.
doi: 10.12688/f1000research.9592.1. eCollection 2016.

Recent advances in understanding and managing psoriatic arthritis

Dafna D Gladman  1
Affiliations
Review

Recent advances in understanding and managing psoriatic arthritis

Dafna D Gladman. F1000Res. .

Abstract

This article reviews recent advances in psoriatic arthritis (PsA) over the past several years with emphasis on early diagnosis, better understanding of pathogenesis, and new therapeutic approaches. Early diagnosis is important, since people who present late do not fare as well. There are a number of clinical, laboratory, and ultrasound features that can help identify patients destined to develop PsA, and several screening tools have been developed. It is recognized that genetic and epigenetic factors, as well as T cells and cytokines, play a role in the pathogenesis of PsA, and several targets have been identified for therapeutic interventions. New therapies have been developed and tested in PsA and have been found to be highly effective for both skin and joint manifestations of the disease. The expectation is that, in the future, PsA patients will be treated early and more aggressively and that there will not be significant progression of joint damage. Moreover, with effective treatment of the skin and joint disease and management of risk factors for the comorbidities, we can expect to reduce their occurrence and further reduce the excess mortality and reduced quality of life and function in these patients.

Keywords: CASPAR; PsA; TNF inhibitors; psoriasis.

PubMed Disclaimer

Conflict of interest statement

The author has consulted for and/or received grants from Amgen, AbbVie, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. No competing interests were disclosed. No competing interests were disclosed.

References

    1. Gladman DD: Clinical Features and Diagnostic Considerations in Psoriatic Arthritis. Rheum Dis Clin North Am. 2015;41(4):569–79. 10.1016/j.rdc.2015.07.003 - DOI - PubMed
    1. Boehncke WH: Etiology and Pathogenesis of Psoriasis. Rheum Dis Clin North Am. 2015;41(4):665–75. 10.1016/j.rdc.2015.07.013 - DOI - PubMed
    1. Ritchlin CT, Kavanaugh A, Gladman DD, et al. : Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2009;68(9):1387–94. 10.1136/ard.2008.094946 - DOI - PMC - PubMed
    1. Helliwell PS, Ruderman EM: Natural History, Prognosis, and Socioeconomic Aspects of Psoriatic Arthritis. Rheum Dis Clin North Am. 2015;41(4):581–91. 10.1016/j.rdc.2015.07.004 - DOI - PubMed
    1. Taylor W, Gladman D, Helliwell P, et al. : Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665–73. 10.1002/art.21972 - DOI - PubMed